On November 7, 2016 Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), reported that abstracts regarding the Company’s allogeneic, off-the-shelf, CAR T programs have been accepted for presentation at the 58th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (Press release, Cellectis, NOV 7, 2016, View Source [SID1234516381]). The meeting will be held December 3-6, 2016 in San Diego.
Oral presentations: • 765 Allogeneic Tcrα/β Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts
View Source Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation Program: Oral and Poster Abstracts Type: Oral Session: 616.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Emerging Immune-Based Therapies for AML Monday, December 5, 2016: 11:00 AM San Diego Ballroom AB (Marriott Marquis San Diego Marina)
Monica L. Guzman, PhD1, Mayumi Sugita, MD1*, Hongliang Zong, MD, PhD1*, Nathan EwingCrystal1*, Vicenta Trujillo-Alonso1*, Nuria Mencia-Trinchant, PhD1*, Linda Lam1*, Nicole M. Cruz, MD1, Roman Galetto, PhD2*, Agnès Gouble, PhD2*, Duane C Hassane, PhD1, Julianne Smith, PhD2 and Gail J. Roboz3
1Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY
2Cellectis SA, Paris, France
3Weill Cornell Medical College, New York, NY
• 381 Preclinical Evaluation of Allogeneic Anti-Bcma Chimeric Antigen Receptor T Cells with Safety Switch Domains and Lymphodepletion Resistance for the Treatment of Multiple Myeloma
View Source
Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy Program: Oral and Poster Abstracts Type: Oral Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immune Approaches for Myeloma Therapy Sunday, December 4, 2016: 12:30 PM Grand Hall B (Manchester Grand Hyatt San Diego)
Bijan Boldajipour, PhD1*, Roman Galetto, PhD2*, Cesar Sommer, PhD1*, Thomas Pertel, PhD1*, Julien Valton, PhD3*, Yoon Park, PhD1*, Annabelle Gariboldi2*, Amy Chen1*, Tao Geng1*, Hong H Dong1*, Gregory R Boucher1*, Thomas J Van Blarcom, PhD1*, Javier Chaparro-Riggers, PhD1*, Arvind Rajpal, PhD1*, Julianne Smith, PhD3, Tracy Kuo, PhD1* and Barbra Sasu, PhD1
1Pfizer Inc., South San Francisco, CA
2Cellectis SA, Paris, France
3Cellectis Inc., New York, NY
Poster presentation:
• 4039 Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
View Source
Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation Program: Oral and Poster Abstracts Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Monday, December 5, 2016, 6:00 PM-8:00 PM Hall GH (San Diego Convention Center)
Tianyu Cai, PhD1*, Roman Galetto, PhD2*, Agnès Gouble, PhD2*, Julianne Smith, PhD2, Antonio Cavazos, MS1*, Sergej Konoplev, MD, PhD3, Andrew A. Lane, MD, PhD4, Monica L. Guzman, PhD5, Hagop M. Kantarjian, MD1, Naveen Pemmaraju, MD1 and Marina Konopleva, MD, PhD1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Cellectis SA, Paris, France
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 4Dana-Farber Cancer Institute, Boston, MA 5Division of Hematology an